Affectis grants Merck's Merck Serono S.A. division exclusive, worldwide rights to oral compounds targeting purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

Affectis Pharmaceuticals AG

Germany / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck KGaA

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced